U.S. Senator Seeks FDA Probe Of Bulk Drug Outsourcing
This article was originally published in PharmAsia News
Executive Summary
A U.S. senator is urging the FDA to take a closer look at producers of bulk drugs based in China and India. Sen. Sherrod Brown, D-Mich., said in a letter to Janet Woodcock, director of the Center for Drug Evaluation & Research, the agency should look into the trend of outsourcing pharmaceutical ingredients. In a separate letter, Brown, a member of a Senate drug oversight committee, also asked Pfizer to provide details of its own practice of outsourcing work to countries that lack the U.S. level of standards for drug safety. (Click here for more